CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS

Immune checkpoints represent the system of inhibitory mechanisms regulating the activation of the immune response, preventing the autoimmune processes and modulating the immune response by decreasing the immune cell-mediated damage of tissues and organs. Tumor cells may utilize these checkpoints to...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	A. V. Bogolyubova, G. A. Efimov, M. S. Drutskaya, S. A. Nedospasov
Format:	article
Langue:	RU
Publié:	SPb RAACI 2015
Sujets:	: сancer immunotherapy immune checkpoints proinflammatory cytokines monoclonal antibody immunology Immunologic diseases. Allergy RC581-607
Accès en ligne:	https://doaj.org/article/803b5b124b054e0eb125b23209da5286
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:803b5b124b054e0eb125b23209da5286
record_format	dspace
spelling	oai:doaj.org-article:803b5b124b054e0eb125b23209da52862021-11-18T08:03:45ZCANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS1563-06252313-741X10.15789/1563-0625-2015-5-395-406https://doaj.org/article/803b5b124b054e0eb125b23209da52862015-10-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/919https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XImmune checkpoints represent the system of inhibitory mechanisms regulating the activation of the immune response, preventing the autoimmune processes and modulating the immune response by decreasing the immune cell-mediated damage of tissues and organs. Tumor cells may utilize these checkpoints to prevent the activation of tumor-specific lymphocytes, thereby acquiring resistance against the immune response. The blockade of inhibitory signal that is transduced in immune checkpoints leading to the reactivation of antitumor immune response is a promising method of tumor immunotherapy. Since the majority of immune checkpoints are based on the ligand-receptor interactions, one of contemporary modalities of anti-tumor therapy is based on the development of ligandor receptor-blocking therapeutic monoclonal antibodies, as well as soluble recombinant receptors capable of competing for a ligand and thereby modulating the signal transduction. In the past few years, this field of tumor immunotherapy experienced an impressive success; however, the potential tradeoff for altering of the natural suppressive mechanisms is the development of the autoimmune reactions.A. V. BogolyubovaG. A. EfimovM. S. DrutskayaS. A. NedospasovSPb RAACIarticle: сancerimmunotherapyimmune checkpointsproinflammatory cytokinesmonoclonal antibodyimmunologyImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 17, Iss 5, Pp 395-406 (2015)
institution	DOAJ
collection	DOAJ
language	RU
topic	: сancer immunotherapy immune checkpoints proinflammatory cytokines monoclonal antibody immunology Immunologic diseases. Allergy RC581-607
spellingShingle	: сancer immunotherapy immune checkpoints proinflammatory cytokines monoclonal antibody immunology Immunologic diseases. Allergy RC581-607 A. V. Bogolyubova G. A. Efimov M. S. Drutskaya S. A. Nedospasov CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
description	Immune checkpoints represent the system of inhibitory mechanisms regulating the activation of the immune response, preventing the autoimmune processes and modulating the immune response by decreasing the immune cell-mediated damage of tissues and organs. Tumor cells may utilize these checkpoints to prevent the activation of tumor-specific lymphocytes, thereby acquiring resistance against the immune response. The blockade of inhibitory signal that is transduced in immune checkpoints leading to the reactivation of antitumor immune response is a promising method of tumor immunotherapy. Since the majority of immune checkpoints are based on the ligand-receptor interactions, one of contemporary modalities of anti-tumor therapy is based on the development of ligandor receptor-blocking therapeutic monoclonal antibodies, as well as soluble recombinant receptors capable of competing for a ligand and thereby modulating the signal transduction. In the past few years, this field of tumor immunotherapy experienced an impressive success; however, the potential tradeoff for altering of the natural suppressive mechanisms is the development of the autoimmune reactions.
format	article
author	A. V. Bogolyubova G. A. Efimov M. S. Drutskaya S. A. Nedospasov
author_facet	A. V. Bogolyubova G. A. Efimov M. S. Drutskaya S. A. Nedospasov
author_sort	A. V. Bogolyubova
title	CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
title_short	CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
title_full	CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
title_fullStr	CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
title_full_unstemmed	CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
title_sort	cancer immunotherapy based on the blockade of immune checkpoints
publisher	SPb RAACI
publishDate	2015
url	https://doaj.org/article/803b5b124b054e0eb125b23209da5286
work_keys_str_mv	AT avbogolyubova cancerimmunotherapybasedontheblockadeofimmunecheckpoints AT gaefimov cancerimmunotherapybasedontheblockadeofimmunecheckpoints AT msdrutskaya cancerimmunotherapybasedontheblockadeofimmunecheckpoints AT sanedospasov cancerimmunotherapybasedontheblockadeofimmunecheckpoints
_version_	1718422430734614528

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS

Documents similaires